Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment ...

Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has ...

The development of CDFAQ-IV was based on theDSM-5 cognitive domains, but its factor analysis has not been done yet. Objectives: To perform a Confirmatory Factor Analysis of the CDFAQ-IV to assess the ...

Soligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the treatment of ...

CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study.